Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REPL Replimune Group Inc.

Trading 06-16 14:00:19 EDT

8.76

-0.20

-2.29%

High8.96	Low8.63	Vol838.12K
Open8.90	D1 Closing8.96	Amplitude3.74%
Mkt Cap722.92M	Tradable Cap437.47M	Total Shares82.57M
T/O7.34M	T/O Rate1.68%	Tradable Shares49.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REPL","market":"US","secType":"STK","nameCN":"Replimune Group Inc.","latestPrice":8.755,"timestamp":1781632816090,"preClose":8.96,"halted":0,"volume":838124,"delay":0,"changeRate":-0.02287946428571429,"floatShares":49968589,"shares":82572600,"eps":-3.435956,"marketStatus":"Trading","change":-0.205,"latestTime":"06-16 14:00:19 EDT","open":8.9,"high":8.96,"low":8.625,"amount":7339274.185712,"amplitude":0.037388,"askPrice":8.76,"askSize":100,"bidPrice":8.75,"bidSize":192,"shortable":3,"etf":0,"ttmEps":-3.435956,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1781640000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1532059200000,"exchange":"NASDAQ","adjPreClose":8.96,"preHourTrading":{"tag":"盘前","latestPrice":8.89,"preClose":8.96,"latestTime":"09:29 EDT","volume":4861,"amount":43205.078405,"timestamp":1781616599999,"change":-0.07,"changeRate":-0.007813,"amplitude":0.046239},"postHourTrading":{"tag":"盘后","latestPrice":8.8506,"preClose":8.96,"latestTime":"19:44 EDT","volume":28439,"amount":254123.9232,"timestamp":1781567051880,"change":-0.1094,"changeRate":-0.01221,"amplitude":0.034598},"volumeRatio":0.502435,"impliedVol":1.0385,"impliedVolPercentile":0.2829},"requestUrl":"/m/hq/s/REPL/wiki","defaultTab":"wiki","newsList":[{"id":"2642495288","title":"U.S. Earnings Preview: Before Market Open June 11","url":"https://stock-news.laohu8.com/highlight/detail?id=2642495288","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642495288?lang=en_us&edition=fundamental","pubTime":"2026-06-11 17:31","pubTimestamp":1781170260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.The following companies are among those expected to report their latest financial results before the market opens.Driven Brands Holdings Inc.'s first-quarter EPS is forecast at 17 cents, compared with 4 cents in the prior-year period. Adjusted EPS is forecast at 24 cents.Replimune Group Inc.'s fourth-quarter EPS is forecast at a loss of 62 cents, compared with a loss of 82 cents in the prior-year period. Adjusted EPS is forecast at a loss of 71 cents.Lovesac Co.'s first-quarter EPS is forecast at a loss of $1.05, compared with a loss of 73 cents in the prior-year period.Hooker Furnishings Corp.'s first-quarter EPS is forecast at a loss of 9 cents, compared with a loss of 29 cents in the prior-year period. Adjusted EPS is forecast at a loss of 6 cents.Vera Bradley Inc.'s first-quarter EPS is forecast at 32 cents, compared with a loss of $1.20 in the prior-year period. Adjusted EPS is forecast ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","BK4192","BK4202","CRMT","BK4095","BK4139","HOFT","BK4214","LOVE","VRA","DRVN","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640715508","title":"U.S. Earnings Preview: Before Market Open June 4","url":"https://stock-news.laohu8.com/highlight/detail?id=2640715508","media":"Dow Jones","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640715508?lang=en_us&edition=fundamental","pubTime":"2026-06-04 17:31","pubTimestamp":1780565460,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.The following companies are among those expected to report their latest financial results before the market opens.Ciena Corp.'s second-quarter EPS is forecast at $1.11, compared with 6 cents in the prior-year period. Adjusted EPS is forecast at $1.46.Toro Co.'s second-quarter EPS is forecast at $1.48, compared with $1.37 in the prior-year period. Adjusted EPS is forecast at $1.51.Replimune Group Inc.'s fourth-quarter EPS is forecast at a loss of 60 cents, compared with a loss of 82 cents in the prior-year period. Adjusted EPS is forecast at a loss of 71 cents.Columbus McKinnon Corp.'s fourth-quarter EPS is forecast at 2 cents, compared with a loss of 9 cents in the prior-year period. Adjusted EPS is forecast at 36 cents.Generated from Dow Jones Calendar Live with data from Dow Jones and Factset.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2357305700.SGD","BK4515","LU0082616367.USD","CMCO","LU0154245673.USD","LU0205193047.USD","BK4139","LU0205194284.USD","CIEN","LU1989764664.SGD","LU0240877869.USD","LU0348723411.USD","LU0154236417.USD","REPL","LU1720051017.SGD","LU1165135440.EUR","LU0823421416.USD","LU0823421333.USD","BK4020","BK4161","LU1543694498.USD","LU0154245756.USD","LU0240878834.USD","LU0012050646.USD","LU0963586101.USD","LU1548497426.USD","LU0106261612.USD","LU0719512351.SGD","TTC","BK4152","LU1720051108.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640138624","title":"Replimune Chief Commercial Officer Christopher Sarchi sells 12,000 shares for $110,880","url":"https://stock-news.laohu8.com/highlight/detail?id=2640138624","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640138624?lang=en_us&edition=fundamental","pubTime":"2026-06-04 08:30","pubTimestamp":1780533043,"startTime":"0","endTime":"0","summary":"Replimune Chief Commercial Officer Christopher Sarchi sold 12,000 common shares on June 1, 2026.Shares were sold at a weighted average price of $9.24.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDLbBCTQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Replimune Chief Commercial Officer Christopher Sarchi sells 12,000 shares for $110,880","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640968058","title":"Replimune Group Is Maintained at Neutral by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2640968058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640968058?lang=en_us&edition=fundamental","pubTime":"2026-06-01 23:30","pubTimestamp":1780327800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REPL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 11:30 ET (15:30 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640522729","title":"Replimune Group trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2640522729","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640522729?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:36","pubTimestamp":1780320990,"startTime":"0","endTime":"0","summary":"09:30 EDT Replimune (REPL) Group trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-mov...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-group-trading-halted-volatility-trading-pause-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-group-trading-halted-volatility-trading-pause-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640952903","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:30 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2640952903","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640952903?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:30","pubTimestamp":1780320659,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:30 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nAQN2M1HH1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640952590","title":"Replimune price target raised to $6 from $2 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2640952590","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640952590?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:07","pubTimestamp":1780319222,"startTime":"0","endTime":"0","summary":"Wedbush raised the firm’s price target on Replimune (REPL) to $6 from $2 and keeps a Neutral rating on the shares. The firm notes the company annou...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-price-target-raised-to-6-from-2-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-price-target-raised-to-6-from-2-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640293759","title":"Replimune Says Evaluating RP2 for Metastatic Uveal Melanoma in Phase 2/3 Trial; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2640293759","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640293759?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:09","pubTimestamp":1780304989,"startTime":"0","endTime":"0","summary":"Replimune  said Sunday it is now evaluating RP2 in combination with nivolumab for metastatic uveal melanoma in a phase 2/3 trial based on results from the phase 1 trial.The company said in its phase 1 first-in-human trial, RP2 monotherapy achieved an objective response rate of 19% in patients with advanced solid tumors. RP2 in combination with nivolumab had an objective response rate of 19.1%, it said.In uveal melanoma, the pooled objective response rate, which included RP2 in combination with nivolumab and RP2 monotherapy, was 33.3%, it said.The phase 1 first-in-human trial had enrolled 85 heavily pretreated patients with advanced solid tumors, including uveal melanoma, colorectal cancer, head and neck cancers, pancreatic cancer, cutaneous melanoma, and sarcoma, the company said.Shares of the company were up over 13% in Monday's premarket activity.Price: 9.90, Change: +1.21, Percent Change: +13.92","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640898722","title":"Replimune Group Inc : JP Morgan Raises to Neutral From Underweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2640898722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640898722?lang=en_us&edition=fundamental","pubTime":"2026-06-01 11:18","pubTimestamp":1780283898,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nFWN4261B6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640866289","title":"Replimune presents final first-in-human data for RP2 alone, with nivolumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2640866289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640866289?lang=en_us&edition=fundamental","pubTime":"2026-06-01 05:15","pubTimestamp":1780262105,"startTime":"0","endTime":"0","summary":"Replimune (REPL) Group presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-presents-final-first-in-human-data-for-rp2-alone-with-nivolumab-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-presents-final-first-in-human-data-for-rp2-alone-with-nivolumab-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640498683","title":"Replimune presents 3-year overall survival data from IGNYTE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640498683","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640498683?lang=en_us&edition=fundamental","pubTime":"2026-06-01 04:35","pubTimestamp":1780259704,"startTime":"0","endTime":"0","summary":"Replimune (REPL) Group presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-P...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-presents-3-year-overall-survival-data-from-ignyte-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-presents-3-year-overall-survival-data-from-ignyte-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639988502","title":"Replimune publishes RP2 Phase 1 ASCO presentation data###","url":"https://stock-news.laohu8.com/highlight/detail?id=2639988502","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639988502?lang=en_us&edition=fundamental","pubTime":"2026-05-31 20:22","pubTimestamp":1780230152,"startTime":"0","endTime":"0","summary":"Replimune published final Phase 1 first-in-human results for RP2, an intratumoral oncolytic HSV-1 immunotherapy, alone or with nivolumab.Safety profile described as well tolerated, with no unexpected toxicity in the nivolumab combination; no grade 4-5 treatment-related adverse events reported.Objective response rate was 19% on RP2 monotherapy  versus 19.1% on RP2 plus nivolumab ; disease control 42.9% versus 48.9%.Median duration of response was not reached on monotherapy; 22.1 months on combination therapy, supporting durability in heavily pretreated solid tumors.Program advanced into a randomized Phase 2/3 trial of RP2 plus nivolumab in metastatic uveal melanoma .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. pu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260531:nNDL2RCh4F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639988531","title":"Replimune says RP2 plus nivolumab posts 19.1% response rate in phase 1 advanced solid tumor trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2639988531","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639988531?lang=en_us&edition=fundamental","pubTime":"2026-05-31 20:00","pubTimestamp":1780228829,"startTime":"0","endTime":"0","summary":"Replimune presented final first-in-human Phase 1 data for RP2, alone or with nivolumab, in advanced solid tumors at the 2026 ASCO meeting.Results showed tumor shrinkage in a meaningful share of heavily pretreated patients, with responses lasting for extended periods in some cases.Activity was seen beyond injected tumors, supporting a broader immune effect that could expand RP2’s addressable use across metastatic disease.Safety looked consistent with expectations, with no unexpected severe treatment-related events reported.The readout supports a randomized Phase 2/3 study of RP2 with nivolumab in metastatic uveal melanoma .","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260531:nNDL6VsxYq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","SG9999014021.USD","REPL","LU2095319765.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","NDAQ","BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639569988","title":"Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639569988","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639569988?lang=en_us&edition=fundamental","pubTime":"2026-05-31 20:00","pubTimestamp":1780228800,"startTime":"0","endTime":"0","summary":"WOBURN, Mass., May  31, 2026  (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today pres","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303918/0/en/Replimune-Presents-Final-First-in-Human-Data-for-RP2-in-Advanced-Solid-Tumors-During-Oral-Presentation-at-the-2026-American-Society-of-Clinical-Oncology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEIS","IE00B7SZL793.SGD","IE00B19Z4B17.USD","LU0757428866.USD","LU1815336091.USD","IE00B66KJ199.SGD","REPL","BK4139","BK4117","MAGE","BK4157","AFG","BK4107","IE0031619046.USD","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639660951","title":"Replimune Group - Rp1 Plus Nivolumab Achieves Median Overall Survival of 32.9 Months in Anti-Pd-1-Failed Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2639660951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639660951?lang=en_us&edition=fundamental","pubTime":"2026-05-30 20:10","pubTimestamp":1780143001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260530:nFWN42615I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639095816","title":"Replimune reports 32.9-month median survival in IGNYTE trial of RP1-nivolumab in anti-PD-1-failed melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2639095816","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639095816?lang=en_us&edition=fundamental","pubTime":"2026-05-30 20:00","pubTimestamp":1780142450,"startTime":"0","endTime":"0","summary":"Replimune presented 3-year overall survival follow-up from IGNYTE at the 2026 ASCO annual meeting on May 30.RP1 with nivolumab showed durable survival in advanced melanoma patients whose disease progressed on prior anti-PD-1 therapy.Benefit appeared sustained in long-term responders, supporting the regimen’s potential to extend disease control in a hard-to-treat setting.Safety remained manageable over extended follow-up, with no new safety concerns flagged in the update.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260530:nNDL1xGNnt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2095319765.USD","BK4112","LU2210149790.SGD","LU0314104364.USD","BK4139","BK4588","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","NDAQ","SG9999014021.USD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","REPL","IE00BN0W2W23.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639609563","title":"Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639609563","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639609563?lang=en_us&edition=fundamental","pubTime":"2026-05-30 20:00","pubTimestamp":1780142400,"startTime":"0","endTime":"0","summary":"WOBURN, Mass., May  30, 2026  (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today pres","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/30/3303875/0/en/Replimune-Presents-3-Year-Landmark-Overall-Survival-Analysis-from-IGNYTE-Clinical-Trial-During-Oral-Presentation-at-the-2026-American-Society-of-Clinical-Oncology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4117","REPL","BK4211","ORR","BK4139","LARK","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639124677","title":"Top News Today: Stocks Rise as Traders Await Iran Deal Confirmation","url":"https://stock-news.laohu8.com/highlight/detail?id=2639124677","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639124677?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:45","pubTimestamp":1780087500,"startTime":"0","endTime":"0","summary":"TREASURYS: Treasury yields were mostly lower as traders weighed mixed economic data and developments in the Middle East.COMMODITIES: Oil futures fell, completing their biggest monthly net decline in New York since March 2020.Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman. UMG's board of directors assessed Pershing Square's unsolicited offer and found that it \"fundamentally and materially undervalues UMG and will not deliver superior value creation.\". \"UMG has built an unrivalled position in the music industry through clear vision and execution,\" said board Chairman Sherry Lansing in a statement, adding that the board has \"full confidence\" in Chief Executive Lucian Grainge and his team.Trump Administration Wants Autos Under USMCA to Be at Least 50% Made in America. International Flavors & Fragrances has agreed to sell its food-ingredients business to buyout firm CVC Capital Partners in a deal that values the division at $","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525689.USD","IE00BFXG1179.USD","UEC","LU2264538146.SGD","BK4141","BK4139","LU0557290698.USD","LU1267930490.SGD","IE0004445239.USD","BK4588","SGXZ81514606.USD","LU0082616367.USD","LU2362541513.USD","LU1854103824.USD","LU0314106906.USD","LU0251132253.USD","IE00B19Z3B42.SGD","LU1551013342.USD","LU1718418525.SGD","LU2361044949.HKD","BK4123","LU1057294990.SGD","BK4533","LU0053666078.USD","LU0683600562.USD","LU0353189763.USD","SG9999014880.SGD","SG9999002224.SGD","LU1988902786.USD","IE00BJJMRZ35.SGD","LU1003077747.HKD","LU0094547139.USD","LU0795875169.SGD","SG9999002232.USD","LU2552382215.SGD","IE0005OL40V9.USD","LU1989771016.USD","SG9999001176.USD","IE00BWXC8680.SGD","IE00BKVL7J92.USD","LU1023059063.AUD","SAIC","IE0002270589.USD","LU0198837287.USD","BK4532","LU2125154935.USD","LU1035773651.USD","LU2244417387.USD","LU0689472784.USD","LU1064131342.USD","LU2089984988.USD","BK4585","LU2360032135.SGD","BK4170","BK4109","IE0004445015.USD","LU0820561818.USD","IE00B7KXQ091.USD","LU1323610961.USD","LU0211327993.USD","LU2290526834.HKD","IE00BJT1NW94.SGD","LU0097036916.USD","LU2089284900.SGD","SG9999018857.SGD","LU0795875086.SGD","LU0672654240.SGD","LU1854104046.USD","IE00BFSS8Q28.SGD","LU2552382058.USD","IE00B1BXHZ80.USD","LU1061106388.HKD","LU0114720955.EUR","IE0009355771.USD","IE00B2B36J28.USD","LU0820562030.AUD","LU1914381329.SGD","LU0048584097.USD","LU1037948897.HKD","LU0345770308.USD","LU0417517546.SGD","LU1506573853.SGD","CRDO","LU1670628061.USD","LU1778281490.HKD","IE00B19Z8X17.USD","LU0985481810.HKD","LU0861579265.USD","SGXZ31699556.SGD","LU0342679015.USD","SGXZ99366536.SGD","LU0738911758.USD","LU0353189680.USD","LU0965509010.AUD","LU2552382132.HKD","LU0348723411.USD","LU0456855351.SGD","BK4606","LU0234572021.USD","CRDU","LU0742534661.SGD","LU0128525929.USD","LU0345770993.USD","BK4156","LU0528227936.USD","LU1069347547.HKD","SG9999014914.USD","HPE","LU0310800965.SGD","LU0320765059.SGD","LU1791710400.SGD","LU1074936037.SGD","LU1861215975.USD","LU0211328371.USD","LU1153585028.USD","LU0985320562.USD","LU0321505439.SGD","IE00B19Z9Z06.USD","LU2125154778.USD","IE00B7SZLL34.SGD","LU0053671581.USD","LU0109391861.USD","SGXZ51526630.SGD","LU2461242641.AUD","IE00B19Z3581.USD","UECG","LU2491050071.SGD","LU0289739699.SGD","IE0009354923.USD","LU1267930227.SGD","LU0158827948.USD","LU1934455863.HKD","LU2023251221.USD","BK4534","LU2279689827.SGD","IE00B775H168.HKD","LU2271345857.HKD","LU2361045086.USD","LU0316494557.USD","LU0965509101.SGD","LU0077335932.USD","LU0266013472.USD","SG9999017495.SGD","LU1674673428.USD","LU0661504455.SGD","LU2360107168.USD","LU0787776722.HKD","LU1291159041.SGD","LU2491049909.HKD","LU0011850046.USD","LU1732800096.USD","LU1496350502.SGD","LU0058720904.USD","IE00B1XK9C88.USD","IE00B19Z9P08.USD","LU1066051811.HKD","LU1066053197.SGD","LU0310800379.SGD","SG9999018865.SGD","LU2361044865.SGD","LU0949170772.SGD","LU1720051108.HKD","LU0708994859.HKD","LU1551013425.SGD","LU2236285917.USD","LU2491050154.USD","SG9999001176.SGD","LU1934455194.USD","LU0496365809.HKD","LU2468319806.SGD","LU0553294199.USD","IFF","LU1861220033.SGD","LU2347655156.SGD","IE00B4JS1V06.HKD","LU1066051498.USD","LU1670627923.USD","IE00B894F039.SGD","LU0719512351.SGD","SG9999013999.USD","LU0225284248.USD","LU2028103732.USD","LU0545039389.USD","LU0048573561.USD","IE00BJJMRX11.SGD","LU0251142724.SGD","LU2211815571.USD","LU0158827781.USD","LU0211326755.USD","LU0052756011.USD","LU2362540622.SGD","BK4561","LU0029864427.USD","IE00BJJMRY28.SGD","BK4566","IE00BKPKM429.USD","IE00BZ9MQY76.HKD","LU0976567544.SGD","LU1267930573.SGD","LU0310799852.SGD","LU1732799900.SGD","IE00B19Z8W00.USD","BK4154","LU0882574055.USD","LU2242649171.HKD","LU1674673691.USD","IE000M9KFDE8.USD","LU0912757837.SGD","LU0965509283.SGD","LU0006061336.USD","BK4504","LU1084165304.USD","LU0079474960.USD","LU1720051017.SGD","LU1267930730.SGD","IE00BZ1G4Q59.USD","LU2089283258.USD","LU2237438978.USD","LU1791710582.SGD","LU0122379950.USD","LU1934455277.USD","LU0354030511.USD","LU2324357040.USD","LYRA","LU1066051225.USD","LU2357305700.SGD","REPL","LU0203347892.USD","LU1983299246.USD","LU0256863811.USD","BK4581","LU0943347566.SGD","LU0354030438.USD","LU0225771236.USD","LU0432979614.USD","LU2112291526.USD","UNH","LU0306807586.USD","LU0251131958.USD","LU0211326839.USD","IE00BSNM7G36.USD","LU0820561909.HKD","IE00BFSS7M15.SGD","LU1814569148.SGD","SG9999014906.USD","IE00B19Z9505.USD","IE0002141913.USD","LU1261432733.SGD","IE00BN29S564.USD","LU1548497426.USD","LU0321505868.SGD","LU0306806265.USD","LU0823416689.USD","LU2133065610.SGD","LU0149725797.USD","BK4007","LU2087625088.SGD","LU0708995401.HKD","LU2362541273.HKD","LU1037948541.HKD","LU0238689110.USD","LU1119994496.HKD","LU0107464264.USD","LU0965508806.USD","LU0187121727.USD","LU2111349929.HKD","SGXZ57979304.SGD","IE00B4R5TH58.HKD","UNHW","IE00BFTCPJ56.SGD","SG9999014898.SGD","UNHG","BK4515","LU0203345920.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639794546","title":"Wedbush Adjusts Price Target on Replimune Group to $6 From $2, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2639794546","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639794546?lang=en_us&edition=fundamental","pubTime":"2026-05-30 00:25","pubTimestamp":1780071959,"startTime":"0","endTime":"0","summary":"Replimune Group (REPL) has an average rating of underweight and mean price target of $2.20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639679910","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2639679910","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639679910?lang=en_us&edition=fundamental","pubTime":"2026-05-30 00:17","pubTimestamp":1780071462,"startTime":"0","endTime":"0","summary":"NetApp  reported fiscal Q4 non-GAAP earnings and revenue late Thursday above market expectations, and its forecast for the full financial year also beat consensus.Shares soared 27% amid a surge in intraday trading volume to over 6.5 million from a daily average of roughly 2.5 million.Dell Technologies  reported overnight fiscal Q1 financial results that topped analyst estimates and issued higher-than-expected guidance for fiscal Q2 and the full year.Shares surged 29% as intraday trading volume catapulted to over 27.1 million from a daily average of about 7.99 million.Replimune  said Friday it will, in the coming days, resubmit a biologics license application with the US Food and Drug Administration for vusolimogene oderparepvec, its experimental treatment for advanced melanoma.Shares catapulted 83% following an increase in intraday trading volume to over 39.8 million from a daily average of about 6.19 million.Price: 180.63, Change: +38.23, Percent Change: +26.85","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4543","DELL","REPL","BK4139","LU0496365809.HKD","LU2065171311.SGD","LU2065169927.USD","NTAP","LU2065170008.USD","LU0942090050.USD","LU1267930227.SGD","LU0211326839.USD","BK4585","LU1823568750.SGD","LU0203347892.USD","LU0211326755.USD","LU0310800965.SGD","BK4535","BK4588","LU0868494708.USD","BK4515","LU0868494617.USD","LU2065171402.SGD","LU0128525689.USD","LU0976567544.SGD","DLLL","LU0052756011.USD","LU1046421795.USD","LU0203345920.USD","LU0267386448.USD","SG9999001440.SGD","BK4170","LU1235294995.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.replimune.com","stockEarnings":[{"period":"1week","weight":-0.0011},{"period":"1month","weight":0.7165},{"period":"3month","weight":0.28},{"period":"6month","weight":-0.0725},{"period":"1year","weight":-0.0838},{"period":"ytd","weight":-0.0782}],"compareEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.1253},{"period":"6month","weight":0.1243},{"period":"1year","weight":0.2644},{"period":"ytd","weight":0.1069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":-0.013766},{"month":2,"riseRate":0.375,"avgChangeRate":-0.050762},{"month":3,"riseRate":0.25,"avgChangeRate":-0.088086},{"month":4,"riseRate":0.5,"avgChangeRate":0.020849},{"month":5,"riseRate":0.5,"avgChangeRate":0.255044},{"month":6,"riseRate":0.875,"avgChangeRate":0.199071},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.088436},{"month":8,"riseRate":0.375,"avgChangeRate":0.023484},{"month":9,"riseRate":0.25,"avgChangeRate":-0.055352},{"month":10,"riseRate":0.625,"avgChangeRate":0.268092},{"month":11,"riseRate":0.625,"avgChangeRate":0.036282},{"month":12,"riseRate":0.25,"avgChangeRate":-0.087028}],"exchange":"NASDAQ","name":"Replimune Group Inc.","nameEN":"Replimune Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Replimune Group Inc.,REPL,Replimune Group Inc.股票,Replimune Group Inc.股票老虎,Replimune Group Inc.股票老虎国际,Replimune Group Inc.行情,Replimune Group Inc.股票行情,Replimune Group Inc.股价,Replimune Group Inc.股市,Replimune Group Inc.股票价格,Replimune Group Inc.股票交易,Replimune Group Inc.股票购买,Replimune Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction